Aclaris Therapeutics, Inc. (ACRS) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 8.22M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $8.22M | (m) | (m) |
| 2026-03-31 | (m) | $8.37M | (m) | (m) |
| 2025-12-31 | (m) | $7.83M | (m) | (m) |
| 2025-09-30 | (m) | $15.74M | (m) | (m) |
| 2025-06-30 | (m) | $16.79M | (m) | (m) |
| 2025-03-31 | (m) | $17.78M | (m) | (m) |
| 2024-12-31 | (m) | $18.72M | (m) | (m) |
| 2024-09-30 | (m) | $27.08M | (m) | (m) |
| 2024-06-30 | (m) | $32.02M | (m) | (m) |
| 2024-03-31 | (m) | $31.12M | (m) | (m) |
| 2023-12-31 | (m) | $31.25M | (m) | (m) |
| 2023-09-30 | (m) | $21.43M | (m) | (m) |
| 2023-06-30 | (m) | $31.17M | (m) | (m) |
| 2023-03-31 | (m) | $30.83M | (m) | (m) |
| 2022-12-31 | (m) | $29.75M | (m) | (m) |
| 2022-09-30 | (m) | $23.50M | (m) | (m) |
| 2022-06-30 | (m) | $6.14M | (m) | (m) |
| 2022-03-31 | (m) | $6.44M | (m) | (m) |
| 2021-12-31 | (m) | $6.76M | (m) | (m) |
| 2021-09-30 | (m) | $6.84M | (m) | (m) |
| 2021-06-30 | (m) | $6.63M | (m) | (m) |
| 2021-03-31 | (m) | $6.85M | (m) | (m) |
| 2020-12-31 | (m) | $6.48M | (m) | (m) |
| 2020-09-30 | (m) | $6.00M | (m) | (m) |
| 2020-06-30 | (m) | $5.53M | (m) | (m) |
| 2020-03-31 | (m) | $4.37M | (m) | (m) |
| 2019-12-31 | (m) | $4.23M | (m) | (m) |
| 2019-09-30 | (m) | $8.84M | (m) | (m) |
| 2019-06-30 | (m) | $16.20M | (m) | (m) |
| 2019-03-31 | (m) | $14.01M | (m) | (m) |
| 2018-12-31 | $3.24M | $10.09M | (m) | 32.12% |
| 2018-09-30 | $3.33M | $7.42M | (m) | 44.82% |
| 2018-06-30 | $3.12M | $6.48M | (m) | 48.20% |
| 2018-03-31 | (m) | (m) | (m) | (m) |
| 2017-12-31 | $476.00K | $1.68M | (m) | 28.28% |
| 2017-09-30 | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |